Generated by AI
BridgeBio Pharma Inc. is a commercial-stage biopharmaceutical company focused on developing medicines for genetic conditions. BridgeBio Pharma Inc. discovers, develops, tests, and delivers therapies aimed at patients with rare and inherited diseases, with programs spanning cardiology, endocrinology, muscle disease, gene therapy, and selected oncology. The company’s current portfolio includes approved medicines such as Attruby for transthyretin amyloid cardiomyopathy and Nulibry for a rare metabolic disorder, alongside a pipeline of investigational treatments for additional genetic disorders. BridgeBio Pharma Inc. works with academic and industry partners to advance precision medicines and bring targeted treatment options to underserved patient groups. Headquartered in Palo Alto, California, BridgeBio Pharma Inc. plays a significant role in the genetic-disease biopharmaceutical market through its mix of commercial products and late-stage development programs.
Website3160 Porter Drive
Palo Alto, CA, 94304
United States
The latest articles about BBIO.
Summary of Nov 16's posts. Generated by AI.
Summary of Apr 28's posts. Generated by AI.
Summary of Apr 28's posts. Generated by AI.
Summary of Feb 28's posts. Generated by AI.
Investors talking about BBIO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.